Sionna Therapeutics SION 深 滬
等待開盤 07-01 09:30:00 美东时间
43.99
+1.020
+2.37%
華盛通- 最 高45.00
- 今 開43.33
- 成交量 68.28万股
- 最 低 42.40
- 昨 收 42.97
- 總市值 198.62万
- 52周最高 48.445
- 市盈率 靜 --
- 換手率 1512.35%
- 52周最低 16.38
- 委 比 2.83%
- 總股本 4.52万
- 歷史最高 48.445
- 量 比 1.18
- 振 幅 6.05%
- 歷史最低 7.255
- 每 手 1
- 風險率 8.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sionna Therapeutics director Peter A. Thompson sells 101 shares for $4,493.49
Sionna Therapeutics director Peter A. Thompson sells 101 shares for $4,493.49 Sionna Therapeutics director Peter A. Thompson reported the sale of 101 shares of common stock on May 27, 2026. Shares were sold at USD 44.49, leaving 2,671,721 shares beneficially owned indirectly. Disclaimer: This news b
05-30 09:03
美股大行评级 | 市值直指1.8万亿美元？瑞银给出美光1600美元天价目标！华尔街绩前集体上调迈威尔科技目标价
今日重点评级关注：Canaccord Genuity：维持Dakota Gold"投机性买入"评级，目标价从16美元升至18美元；瑞杰金融：上调Tectonic Therapeutic评级至"强烈买入"，目标价从76美元升至81美元
05-27 17:33
Citizens Reiterates Market Outperform on Sionna Therapeutics, Maintains $63 Price Target
Citizens analyst Jonathan Wolleben reiterates Sionna Therapeutics (NASDAQ:SION) with a Market Outperform and maintains $63 price target.
05-26 21:24
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
Stifel Maintains Buy on Sionna Therapeutics, Raises Price Target to $55
Stifel analyst Paul Matteis maintains Sionna Therapeutics (NASDAQ:SION) with a Buy and raises the price target from $44 to $55.
05-19 00:56
U.S. RESEARCH ROUNDUP-Exxon Mobil, Northrop Grumman, Regeneron Pharmaceuticals
U.S. RESEARCH ROUNDUP-Exxon Mobil, Northrop Grumman, Regeneron Pharmaceuticals May 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Exxon Mobil, Northrop Grumman and Regeneron Pharmaceuticals on Monday. HIGHLIGHTS * Ch
05-18 15:15
Sionna Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results.
Sionna Therapeutics shares are trading lower after the company reported worse-t...
05-12 23:17
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
Sionna Therapeutics Q1 EPS $(0.60) Misses $(0.51) Estimate
Sionna Therapeutics (NASDAQ:SION) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.51) by 17.65 percent. This is a 3.23 percent increase over losses of $(0.62) per share
05-12 19:10
Sionna Therapeutics Reports First Quarter 2026 Financial Results
Sionna Therapeutics reported the completion of enrollment in its Phase 2a trial for SION-719, an NBD1 stabilizer for cystic fibrosis, with topline data expected in summer 2026. The company also noted progress in its Phase 1 trial for SION-451, with dual combination data anticipated in the same timeframe. Sionna maintained a strong cash position of $289.9 million, supporting operations into 2028.
05-12 11:00
